Latest News on ANNX

Financial News Based On Company


Advertisement
Advertisement

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/11/17/3405167/0/en/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4.html
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved on November 14, 2026. The employee received an option to purchase 300,000 shares of common stock at an exercise price of $3.92, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the biopharmaceutical company focused on neuroinflammatory diseases.

Three parties report shared voting power over 8.28M Annexon (ANNX) shares.

https://www.stocktitan.net/sec-filings/ANNX/schedule-13g-a-annexon-inc-amended-passive-investment-disclosure-d0a4a45d62d9.html
BVF Partners L.P., BVF Inc., and Mark N. Lampert have jointly reported beneficial ownership of 8,278,164 shares of Annexon, Inc. (ANNX), representing approximately 4.4% of the outstanding shares as of September 30, 2026. This disclosure was made via an Amendment No. 5 to a Schedule 13G filing, indicating shared voting and dispositive power over these shares. The filing details the breakdown of ownership among various Biotechnology Value Funds.

Annexon (NASDAQ:ANNX) Cuts Research Spending and Posts a Smaller Quarterly Loss

https://kalkine.ca/news/healthcare/annexon-nasdaqannx-cuts-research-spending-and-posts-a-smaller-quarterly-loss
Annexon (NASDAQ:ANNX) reported a smaller-than-expected loss of USD 0.25 per share in Q3 2026, against an anticipated USD 0.28 loss. The net loss for the quarter was USD 51.22 million, an improvement from USD 54.92 million a year earlier, primarily driven by a 17% reduction in research and development expenses. The company's cash and cash equivalents stood at USD 102.39 million as of September 30, 2026.

Annexon, Inc. (ANNX) stock price, news, quote and history

https://au.finance.yahoo.com/quote/ANNX/
This page provides a comprehensive overview of Annexon, Inc. (ANNX) stock, including its current price, historical data, and key financial metrics. It details the company's profile as a clinical-stage biopharmaceutical company developing treatments for inflammatory-related diseases, along with recent performance, earnings trends, and analyst ratings. The article also lists other related stocks in the biotechnology sector.

Annexon, Inc. (ANNX) Tops Q3 EPS by 3c

https://www.streetinsider.com/Earnings/Annexon%2C+Inc.+%28ANNX%29+Tops+Q3+EPS+by+3c/27316529.html
Annexon, Inc. (NASDAQ: ANNX) reported its Q3 earnings, surpassing analyst estimates by $0.03 with an EPS of ($0.25) against an expected ($0.28). This performance information is relevant for investors tracking the company's financial health. The stock price remained at $4.23 following the announcement.
Advertisement

A $50M draw at closing starts Annexon (ANNX)'s credit deal with Oxford Finance.

https://www.stocktitan.net/sec-filings/ANNX/8-k-annexon-inc-reports-material-event-8851430741cc.html
Annexon, Inc. secured an "up to $200 million" credit facility with Oxford Finance LLC, drawing $50 million at closing. The remaining $150 million is tied to program milestones and lender approval, bolstering the company's financial position to fund operations into 2028. This announcement coincided with Annexon's Q3 2026 financial results, which showed a narrowed net loss and progress in its clinical programs for Guillain-Barré syndrome (GBS), geographic atrophy (GA), and other autoimmune diseases.

ANNX: SEC Form 10-Q filed by Annexon Inc.

https://www.quantisnow.com/insight/sec-form-10-q-filed-by-annexon-inc-6781335
Annexon Inc. (ANNX) filed its 10-Q for Q3 2026, reporting 190.8 million shares outstanding as of November 5, 2026, and an additional 14.7 million shares issuable from pre-funded warrants. The company raised $32.7 million net through its at-the-market (ATM) stock sales in the first nine months of 2026 before terminating the program in May 2026. This filing indicates shareholder dilution and a continued net loss.

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

https://www.globenewswire.com/news-release/2026/11/09/3398918/0/en/annexon-reports-third-quarter-2026-financial-results-business-updates-and-key-anticipated-milestones.html
Annexon, Inc. (Nasdaq: ANNX) reported its third quarter 2026 financial results, highlighting progress in its C1q platform with two registrational programs for neuroinflammatory diseases. The company is advancing tanruprubart for Guillain-Barré syndrome (GBS), with a U.S. BLA submission anticipated in Q4 2026, and vonaprument for geographic atrophy (GA), with Month 15 primary endpoint assessment of the ARCHER II Phase 3 trial expected in Q4 2026. Annexon ended the quarter with $213.4 million in cash, cash equivalents, and short-term investments, providing an anticipated operational runway into 2028.

Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow

https://seekingalpha.com/article/4964781-annexon-inc-annx-discusses-vonaprument-phase-iii-archer-ii-trial-in-geographic-atrophy
Annexon, Inc. (ANNX) has published a slide deck related to its Vonaprument Phase III ARCHER II trial for Geographic Atrophy. This release provides insights into the company's clinical development and research in this area. The information was shared in conjunction with an event.

Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug

https://www.tradingview.com/news/marketbeat:70da1ead0094b:0-annexon-eyes-q4-2026-phase-iii-readout-for-vision-preserving-ga-drug/
Annexon (ANNX) anticipates reporting the month-15 primary-endpoint analysis from its Phase III ARCHER II trial for vonaprument, a geographic atrophy (GA) treatment, in Q4 2026. The study focuses on vision preservation, a key concern for GA patients, rather than just lesion growth, distinguishing it from existing FDA-approved therapies. Positive results from this larger and longer trial could position vonaprument as a significant new option for GA, potentially changing treatment discussions and improving adherence.
Advertisement

ANNX: ARCHER II’s month-15 vision-loss readout is expected in Q4 2026

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4440651:0-annx-archer-ii-s-month-15-vision-loss-readout-is-expected-in-q4-2026/
Annexon, Inc. (ANNX) announced that the month-15 vision-loss readout for its ARCHER II trial is anticipated in Q4 2026. The ARCHER phase II study demonstrated dose-dependent vision protection, including a 73% reduction in the risk of confirmed 15-letter loss compared to sham. The ARCHER II trial enrolled 659 patients, with two sub-study analyses to follow in Q1 2027.

ANNX: Phase 2 showed dose-dependent vision protection; ARCHER II’s 15-month analysis is targeted for Q4 2026

https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:4365554:0-annx-phase-2-showed-dose-dependent-vision-protection-archer-ii-s-15-month-analysis-is-targeted-for-q4-2026/
Annexon (ANNX) announced positive results from its Phase 2 ARCHER study, showing dose-dependent reductions in vision loss, particularly with the EM dose. The company's ARCHER II study, which has enrolled 659 patients, is targeting its 15-month primary analysis for Q4 2026. This news was based on slides released by Annexon, Inc. on November 3, 2026.

Annexon, Inc. Estimates – NASDAQ:ANNX

https://www.tradingview.com/symbols/NASDAQ-ANNX/financials-estimates/
This article provides an overview of Annexon, Inc. (NASDAQ:ANNX) financial estimates available on TradingView. It details how users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows for comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Annexon, Inc. (ANNX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ANNX/seasonality/
This article from Yahoo Finance presents a seasonality chart for Annexon, Inc. (ANNX), displaying the average monthly price return for the period between 2020 and 2026. It includes current stock price data for ANNX, showing its performance both at market close and in after-hours trading. The article focuses solely on the stock's seasonal trends without offering further analysis.

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

https://www.globenewswire.com/news-release/2026/10/28/3390122/0/en/annexon-to-host-virtual-investor-event-on-november-3-2026-vonaprument-for-the-treatment-of-geographic-atrophy-highlighting-key-aspects-of-phase-3-archer-ii-trial.html
Annexon, Inc. (Nasdaq: ANNX) announced it will host a virtual investor event on November 3, 2026, at 11:00 AM ET to discuss the ARCHER II Phase 3 program for vonaprument in treating geographic atrophy. Company management and Dr. Roger Goldberg will highlight the trial design, patient demographics, and communication strategy for upcoming 15-month and 24-month results. The event will also address the unmet need and current treatment landscape for geographic atrophy.
Advertisement

Annexon schedules investor event on phase 3 trial Nov. 3 By Investing.com

https://www.investing.com/news/company-news/annexon-schedules-investor-event-on-phase-3-trial-nov-3-93CH-4978862
Annexon Inc. will host a virtual investor event on Tuesday, November 3, 2026, at 11:00 AM ET to discuss its ARCHER II Phase 3 program. The company will detail the clinical trial design, patient demographics, and communication strategy for anticipated 15-month and 24-month results, which are expected to begin in Q4 2026. Dr. Roger Goldberg will also participate to discuss the unmet need for geographic atrophy treatments.

Annexon schedules investor event on phase 3 trial Nov. 3 By Investing.com

https://uk.investing.com/news/stock-market-news/annexon-schedules-investor-event-on-phase-3-trial-nov-3-93CH-4937361
Annexon Inc. (NASDAQ:ANNX) is set to host a virtual investor event on November 3, 2026, at 11:00 AM ET to discuss its ARCHER II Phase 3 program. The event will detail the clinical trial design, patient demographics, and communication strategy for upcoming 15-month and 24-month results, expected to begin in the fourth quarter of 2026. Management will also discuss recent additions to its ophthalmology team, with Dr. Roger Goldberg participating to address the unmet need in geographic atrophy.

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

https://sg.finance.yahoo.com/news/annexon-host-virtual-investor-event-120000456.html
Annexon, Inc. (Nasdaq: ANNX) will host a virtual investor event on November 3, 2026, at 11:00 AM ET to discuss its ARCHER II Phase 3 program for vonaprument, a treatment for geographic atrophy. The event will cover the clinical trial design, patient demographics, and communication strategy for upcoming 15-month and 24-month results, featuring Dr. Roger Goldberg to discuss the unmet need for the condition.

Annexon, Inc. Estimates – BOATS:ANNX

https://www.tradingview.com/symbols/BOATS-ANNX/financials-estimates/
This page on TradingView provides financial estimates and actual data for Annexon, Inc. (ANNX) under the Blue Ocean Alternative Trade System. Users can explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform also allows for comparisons between actual results and average, high, and low estimates.

H.C. Wainwright raises Annexon stock price target on GBS approval prospects

https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-annexon-stock-price-target-on-gbs-approval-prospects-93CH-4890630
H.C. Wainwright has increased its price target for Annexon Biosciences (NASDAQ:ANNX) to $25 from $14, maintaining a Buy rating, citing the potential approval of tanruprubart for Guillain-Barré syndrome (GBS) and the upcoming ARCHER II readout for vonaprument in geographic atrophy. The firm values tanruprubart at $11.70 per share with a 90% success probability and vonaprument at $13.60 per share with a 40% success probability, noting that a positive ARCHER II result could raise the fair value to approximately $44. Despite a 38% stock decline over six months, the company's strong balance sheet and oversold RSI suggest potential upside, even with a high annual cash burn.
Advertisement

HC Wainwright & Co. maintains Buy rating on Annexon, $25 price target

https://www.tradingview.com/news/tradingview:0c09457fa2955:0-hc-wainwright-co-maintains-buy-rating-on-annexon-25-price-target/
HC Wainwright & Co. has reiterated its Buy rating for Annexon (ANNX) with a price target of $25.00, suggesting a significant upside of 633.1% from its recent closing price. The firm highlights Annexon's strong pipeline, which focuses on classical complement-mediated disorders, addressing significant unmet medical needs in autoimmune and neurodegenerative diseases. This positive analyst sentiment reflects confidence in the company's growth potential and the successful commercialization of its innovative therapies.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/10/17/tmt-newswire/globenewswire/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635c4/2447798
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to six new non-executive employees under its 2022 Employment Inducement Award Plan, approved according to Nasdaq Listing Rule 5635(c)(4). These grants include options to purchase 1,270,000 shares of common stock, with an exercise price of $3.60, vesting over four years. The company specializes in developing immunotherapies for neuroinflammatory diseases.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/10/16/3382822/0/en/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4.html
Annexon, Inc. (Nasdaq: ANNX) announced that it has granted inducement awards to six new non-executive employees under its 2022 Employment Inducement Award Plan. These awards, approved on October 7, 2026, consist of options to purchase 1,270,000 shares of common stock at an exercise price of $3.60, vesting over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon Price Target Raised to $15.00/Share From $14.00 by JP Morgan

https://www.moomoo.com/news/post/1000477605/annexon-price-target-raised-to-15-00-share-from-14
JP Morgan has increased its price target for Annexon from $14.00 to $15.00 per share. This adjustment indicates a positive outlook from the financial institution regarding Annexon's future stock performance.

JPMorgan raises Annexon Biosciences price target on trial data By Investing.com

https://ca.investing.com/news/stock-market-news/jpmorgan-raises-annexon-biosciences-price-target-on-trial-data-93CH-4860385
JPMorgan increased its price target for Annexon Biosciences (NASDAQ:ANNX) to $15.00 from $14.00, maintaining an Overweight rating, based on the anticipated Phase 3 ARCHER II study results for vonaprument. The stock is currently trading at $4.08, implying a potential 267% upside, with key 15-month trial data expected in Q4 2026. Despite a year-to-date decline, the stock has gained 35% over the past year and InvestingPro analysis suggests it is slightly undervalued, holding more cash than debt, though it is burning through cash.
Advertisement

Insider Spends US$100k Buying More Shares In Annexon

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-annx/annexon/news/insider-spends-us100k-buying-more-shares-in-annexon
Annexon's CEO, President & Director, Douglas Love, recently purchased US$100k worth of company stock. While this individual purchase signals confidence, the overall insider transaction history for the past year shows more selling than buying. Insiders collectively own 0.9% of Annexon shares, valued at US$6.2 million.

Annexon (ANNX) President and CEO Douglas Love Buys 26,065 Shares

https://www.gurufocus.com/news/9098066/annexon-annx-president-and-ceo-douglas-love-buys-26065-shares
Douglas Love, President and CEO of Annexon Inc (ANNX), recently purchased 26,065 shares of the company on September 24, 2026, increasing his total holdings to 390,476 shares. The transaction, valued at $3.83 per share, signals confidence from the executive in the clinical-stage biopharmaceutical company, which focuses on developing treatments for autoimmune, neurodegenerative, and ophthalmic diseases. This insider buy contributes to a slightly positive insider activity trend for Annexon over the past year, with 12 buys versus 10 sells.

After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares.

https://www.stocktitan.net/sec-filings/ANNX/form-4-annexon-inc-insider-trading-activity-72f9c9a89728.html
Annexon, Inc. President and CEO Love Douglas purchased 26,065 shares of common stock on September 24, 2026, at a weighted average price of $3.83 per share, bringing his direct holdings to 390,476 shares. The transaction, executed in multiple trades ranging from $3.815 to $3.829, was reported as a neutral filing with positive sentiment.

More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings.

https://www.stocktitan.net/news/ANNX/annexon-to-present-patient-baseline-characteristics-from-vonaprument-jzh6cnkeiv3n.html
Annexon (ANNX) will present data from its vonaprument Phase 3 ARCHER II trial and a post hoc analysis of Phase 2 vision outcomes at The Retina Society's annual meeting on September 25, 2026. The presentations will cover baseline characteristics of participants in the ARCHER II trial for geographic atrophy (GA), a leading cause of blindness, and highlight findings from the Phase 2 ARCHER study. Month 15 results for the ARCHER II trial are expected in Q4 2026, with vonaprument designed as a potential first-in-kind vision-protecting therapy for GA.

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

https://www.globenewswire.com/news-release/2026/09/24/3368269/0/en/annexon-to-present-patient-baseline-characteristics-from-vonaprument-phase-3-archer-ii-pivotal-trial-for-geographic-atrophy-at-the-retina-society-59th-annual-scientific-meeting.html
Annexon, Inc. announced two oral presentations at The Retina Society 59th Annual Scientific Meeting regarding vonaprument for geographic atrophy (GA). The presentations will highlight patient baseline characteristics from the Phase 3 ARCHER II trial and vision outcomes from the Phase 2 ARCHER trial, aiming to demonstrate vonaprument's potential to protect vision in GA patients. Results from the ARCHER II trial are anticipated in the fourth quarter of 2026.
Advertisement

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

https://investingnews.com/annexon-to-present-patient-baseline-characteristics-from-vonaprument-phase-3-archer-ii-pivotal-trial-for-geographic-atrophy-at-the-retina-society-59th-annual-scientific-meeting/
Annexon, Inc. will present patient baseline characteristics from its Phase 3 ARCHER II pivotal trial for vonaprument in geographic atrophy (GA) at The Retina Society 59th Annual Scientific Meeting. The presentations will highlight how Phase 2 vision protection findings informed the Phase 3 trial design and demonstrate the replication of key baseline clinical characteristics, positioning ARCHER II to confirm vonaprument's potential to protect vision in GA. Vonaprument, designed to inhibit C1q, has received Fast Track designation from the FDA and PRIME designation from the EMA.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

https://www.marketscreener.com/news/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-ce785bd2d18afe26
Annexon, Inc. announced inducement grants to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved in accordance with Nasdaq Listing Rule 5635(c)(4). These grants include options to purchase 275,500 shares of Annexon common stock at an exercise price of $3.92 per share, vesting over four years. The biopharmaceutical company focuses on advancing immunotherapies for neuroinflammatory diseases.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

https://finance.yahoo.com/healthcare/articles/annexon-reports-inducement-grants-employees-200500170.html
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on September 12, 2026. These grants, totaling options to purchase 275,500 shares of common stock at an exercise price of $3.92, vest over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent for the biopharmaceutical company focused on neuroinflammatory diseases.

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com

https://ng.investing.com/news/stock-market-news/annexon-at-cantor-fitzgerald-conference-eye-data-gbs-progress-93CH-2692171
Annexon presented at the Cantor Fitzgerald Global Healthcare Conference, highlighting positive clinical data for its two late-stage neuroinflammatory disease programs. The company's lead eye drug, vonaprument, showed significant vision preservation in geographic atrophy, with an enrollment ahead of schedule for its Phase III ARCHER II study. Additionally, Annexon reported a 100% response rate in open-label data for its Guillain-Barré syndrome program, with regulatory filings underway in Europe and planned for the FDA.

Annexon to Participate in Upcoming September Investor Conferences

https://finance.yahoo.com/healthcare/articles/annexon-participate-upcoming-september-investor-120000705.html
Annexon, Inc. (Nasdaq: ANNX) announced that its President & CEO, Douglas Love, will participate in three upcoming investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts of these presentations will be available on Annexon's website, with replays archived for 30 days. The company focuses on developing targeted immunotherapies for neuroinflammatory diseases.
Advertisement

Annexon to Participate in Upcoming September Investor Conferences

https://investingnews.com/annexon-to-participate-in-upcoming-september-investor-conferences/
Annexon, Inc. (Nasdaq: ANNX) announced that its President & CEO, Douglas Love, will participate in three upcoming investor conferences in September 2026. These include the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts and replays will be available on Annexon's investor relations website.

ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10

https://www.moomoo.com/news/flash/23120166/annexon-inc-jp-morgan-raises-target-price-to-14-from
JP Morgan has increased its target price for ANNEXON, INC. shares from $10 to $14. This revision suggests an improved outlook from the financial institution regarding the company's future stock performance.

Annexon to Participate in Upcoming September Investor Conferences

https://www.globenewswire.com/news-release/2026/09/02/3355070/0/en/annexon-to-participate-in-upcoming-september-investor-conferences.html
Annexon, Inc. (Nasdaq: ANNX) announced that its president & chief executive officer, Douglas Love, will participate in several investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, Cantor Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts of these presentations will be available on the company's website, with replays archived for 30 days. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.

Annexon Biosciences Bets Big on Pivotal Trial Wins

https://www.tipranks.com/news/company-announcements/annexon-biosciences-bets-big-on-pivotal-trial-wins
Annexon Biosciences presented an optimistic outlook during its Q2 earnings call, highlighting significant clinical progress with tanruprubart for Guillain-Barré syndrome (GBS) and disciplined execution in geographic atrophy (GA) trials. The company also secured a non-dilutive credit facility, extending its cash runway into 2028. While acknowledging statistical complexities and debt obligations, Annexon remains confident in its pipeline and regulatory timelines, anticipating a period rich in catalysts.

Annexon, Inc. (ANNX) Net Income 2025: $206.7M net loss, down 49.6%

https://www.stocktitan.net/financials/ANNX/net-income/
Annexon, Inc. (ANNX) reported a net loss of $206.7 million in fiscal year 2025, marking a 49.6% decrease from the previous fiscal year. Over the past seven fiscal years, the company's net income has trended from a loss of -$37.2 million in 2019 to -$206.7 million in 2025. In the most recent quarter (Q2 2026), ANNX recorded a net loss of -$55.3 million, a 12.6% decrease year-over-year.
Advertisement

Annexon, Inc. (ANNX) Free Cash Flow 2025: $186.5M outflow, down 58.0%

https://www.stocktitan.net/financials/ANNX/free-cash-flow/
Annexon, Inc. (ANNX) reported a free cash flow outflow of $186.5 million in fiscal year 2025, marking a 58.0% decrease from the previous year. Over the trailing 12 months (Q3 FY2025 through Q2 FY2026), the company recorded a free cash flow outflow of $193.2 million. This article provides a detailed breakdown of ANNX's annual and quarterly free cash flow figures from 2019 to 2026, alongside explanations of what free cash flow represents.

Annexon (ANNX) Institutional Ownership 2026

https://www.marketbeat.com/stocks/NASDAQ/ANNX/institutional-ownership/
This article details the institutional ownership of Annexon (ANNX) as of 2026, providing data on institutional buyers and sellers, total inflows and outflows, and a list of major shareholders with their respective holdings and market values. It highlights that 105 institutional buyers invested $315.19M in the last 12 months, while 30 institutional sellers divested $18.85M. Key shareholders include Palo Alto Investors LP, Redmile Group LLC, and BlackRock Inc.

Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside

https://www.tradingview.com/news/tradingview:296dcfbfce7aa:0-annexon-inc-stock-12-month-price-target-raised-to-15-71-implies-198-upside/
Annexon, Inc.'s average stock price target has been increased to $15.71 from $15 by 7 analysts, with forecasts ranging from $7 to $27 per share. This new target suggests a potential upside of approximately 198% based on the recent closing price. The consensus rating for ANNX remains a "Buy" from 10 analysts.

Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-2360-million-stock-holdings-in-annexon-inc-annx-2026-08-18/
Bank of America Corp DE significantly increased its stake in Annexon, Inc. (NASDAQ:ANNX) during the first quarter, now holding 4,259,995 shares valued at $23.60 million. Other institutional investors have also adjusted their positions, and a company director recently acquired over 600,000 shares. Annexon, a clinical-stage biotechnology company focusing on neurodegenerative and neuroimmune diseases, has seen varied analyst ratings, with an average "Hold" rating and a target price of $15.33.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/08/18/tmt-newswire/globenewswire/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635c4/2407130/amp
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to three new non-executive employees under the 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These employees received options to purchase 287,500 shares of Annexon common stock at an exercise price of $5.29, vesting over four years. This initiative aims to attract and retain talent for the biopharmaceutical company focused on neuroinflammatory diseases.
Advertisement

At $5.29, Annexon grants new employees options vesting over four years

https://www.stocktitan.net/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-cbya2arbo6cr.html
Annexon (Nasdaq: ANNX) announced inducement grants of options to purchase 287,500 shares of common stock to three new non-executive employees. These options, granted at an exercise price of $5.29 per share, vest over four years, with 25% on the first anniversary and the remainder monthly. The grants were made under the 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen

https://www.marketbeat.com/instant-alerts/annexon-nasdaqannx-rating-lowered-to-strong-sell-at-wall-street-zen-2026-08-15/
Wall Street Zen has downgraded Annexon (NASDAQ:ANNX) from a "sell" to a "strong sell" rating. This decision comes despite some other analysts maintaining "buy" or "hold" ratings for ANNX, with a consensus price target of $15.33. The company recently reported Q2 earnings, missing analyst estimates, and has seen significant insider stock purchases.

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed

https://www.sahmcapital.com/news/content/annexon-annx-is-down-61-after-dual-endpoint-shift-in-archer-ii-trial-whats-changed-2026-08-14
Annexon (ANNX) experienced a 6.1% decline in share price following the adoption of a dual primary endpoint in its ARCHER II trial for vonaprument, affecting its investment narrative. Despite a wider Q2 2026 net loss of US$55.35 million, the company secured up to US$200 million in non-dilutive financing, extending its cash runway into 2028. This shift introduces a second assessment point at Month 24 for the trial, potentially broadening regulatory evaluation of the drug's vision-preserving benefits.

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

https://investingnews.com/annexon-expands-vonaprument-phase-3-program-in-geographic-atrophy-with-addition-of-month-24-dual-primary-endpoint-complementing-month-15-primary-endpoint-and-launch-of-open-label-extension-study/
Annexon, Inc. announced an expansion of its vonaprument Phase 3 ARCHER II trial for geographic atrophy (GA), adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint. This strategy allows for success at either time point and will enable evaluation of the long-term profile of vonaprument. The company also launched an open-label extension study to assess long-term safety and benefits, with Month 15 data expected in Q4 2026 and Month 24 analyses anticipated in Q3 2027.

Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise

https://www.stocktitan.net/sec-filings/ANNX/144-annexon-inc-sec-filing-f3513319f04a.html
An individual affiliated with Annexon, Inc. (ANNX) has filed a Form 144 notice indicating an intent to sell 2,000 shares of common stock on August 13, 2026. These shares will be acquired through a same-day stock option exercise for cash. The filing also reports prior sales by Thomas Wiggans in July 2026, totaling 3,000 shares for an aggregate of $18,235.00.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement